Suppr超能文献

重组脂蛋白相关凝血抑制剂可抑制兔体内组织凝血活酶诱导的血管内凝血。

Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit.

作者信息

Day K C, Hoffman L C, Palmier M O, Kretzmer K K, Huang M D, Pyla E Y, Spokas E, Broze G J, Warren T G, Wun T C

机构信息

Monsanto Corporate Research, Chesterfield, MO 63198.

出版信息

Blood. 1990 Oct 15;76(8):1538-45.

PMID:2207329
Abstract

Lipoprotein-associated coagulation inhibitor produces feed-back inhibition of tissue factor (tissue thromboplastin)-induced coagulation in the presence of factor Xa Recombinant lipoprotein-associated coagulation inhibitor (rLACI) was tested for its ability to modify thromboplastin-induced intravascular coagulation in a rabbit model that allows monitoring of iodine-125 fibrin accumulation/disappearance in the lung and sampling of blood for the measurement of coagulation parameters. Infusion of thromboplastin into the rabbit caused a rapid increase of radioactivity over the lungs, possibly due to the accumulation of 125I fibrin in the lungs, followed by a rapid decline of radioactivity, suggestive of removal of fibrin from the lungs. Thromboplastin also caused a rapid decrease of systemic fibrinogen that was accompanied by a lengthening of the activated partial thromboplastin time and prothrombin time. The effect of coinfusion of rLACI with thromboplastin or bolus injection of rLACI before thromboplastin infusion was studied. At a high dose of rLACI (800 micrograms/kg body weight), the thromboplastin-induced radioactivity increase in the lungs and the systemic fibrinogen decrease were completely suppressed. The activated partial thromboplastin time and prothrombin time of the plasma samples lengthened, possibly due to the presence of thromboplastin in circulation. The thromboplastin-induced radioactivity increase over the lungs was not completely suppressed by lower doses of rLACI (135 to 270 micrograms/kg body weight), but these doses of rLACI prevented systemic fibrinogen decrease. At a bolus dose of 23 micrograms/kg body weight, rLACI provided 50% protection of the fibrinogen consumption (fibrinogen decreased to 82% compared with 65% in rabbits treated with thromboplastin alone). These results show that rLACI is effective in the inhibition of thromboplastin-induced coagulation in vivo.

摘要

脂蛋白相关凝血抑制剂在因子Xa存在的情况下对组织因子(组织凝血活酶)诱导的凝血产生反馈抑制作用。在一个兔模型中测试了重组脂蛋白相关凝血抑制剂(rLACI)改变凝血活酶诱导的血管内凝血的能力,该模型可监测肺中碘-125纤维蛋白的积累/消失,并采集血液样本以测量凝血参数。向兔体内注入凝血活酶导致肺部放射性迅速增加,这可能是由于肺中125I纤维蛋白的积累,随后放射性迅速下降,提示纤维蛋白从肺中清除。凝血活酶还导致全身纤维蛋白原迅速减少,同时活化部分凝血活酶时间和凝血酶原时间延长。研究了rLACI与凝血活酶共同注入或在注入凝血活酶前大剂量注射rLACI的效果。在高剂量rLACI(800微克/千克体重)时,凝血活酶诱导的肺部放射性增加和全身纤维蛋白原减少被完全抑制。血浆样本的活化部分凝血活酶时间和凝血酶原时间延长,可能是由于循环中存在凝血活酶。较低剂量的rLACI(135至270微克/千克体重)并未完全抑制凝血活酶诱导的肺部放射性增加,但这些剂量的rLACI可防止全身纤维蛋白原减少。在23微克/千克体重的大剂量下,rLACI对纤维蛋白原消耗提供了50%的保护作用(纤维蛋白原降至82%,而单独用凝血活酶治疗的兔为65%)。这些结果表明,rLACI在体内可有效抑制凝血活酶诱导的凝血。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验